chempartner.com Listed by lockbit3 Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On February 13, 2023, the ransomware group known as lockbit3 listed chempartner.com on its leak site, claiming responsibility for a ransomware attack in which internal files were exfiltrated. Public reporting associated with that listing describes a claimed volume of 281 GB of material. The number of people affected remains unknown, and independent confirmation of the full scope has not been detailed in the available record.

For an organisation that supports chemistry and pharmaceutical research, any confirmed exposure of internal project and supply-related files carries practical consequences for partners, clients, and staff. What follows summarises only what has been reported, distinguishes claims from verified fact, and outlines why the incident matters and what individuals can do next.

Breaking down the breach

According to the public listing attributed to lockbit3, chempartner.com was the target of a ransomware attack in which internal files were taken. The reported date associated with the disclosure is February 13, 2023. The listing and related summary describe roughly 281 GB of downloaded information, characterised as including company analytics, project information, reports, and information on drug supplies, among other internal material.

No public figure has been given for the number of individuals affected. Technical details of how the attackers gained access—initial vector, dwell time, or encryption status—are not disclosed in the available facts. The incident is therefore best understood as a claimed double-extortion event: data theft paired with a leak-site threat, rather than a fully independently documented forensic account. Readers should treat the group’s description of contents and volume as its claim unless and until the organisation or regulators publish confirming detail.

Who is lockbit3?

Lockbit3 is a well-documented ransomware operation that has operated as a ransomware-as-a-service model, enabling affiliates to deploy its encryptor and share in extortion proceeds. Like other major ransomware brands, it has commonly used double extortion: stealing data before or during encryption, then threatening to publish it on a dedicated leak site if payment is not made. The group has been linked over successive years to attacks across many sectors and geographies, and its leak site has been used to name alleged victims and, in some cases, to stage partial releases of stolen files.

Public knowledge of lockbit3’s tactics does not, by itself, prove every detail of any single listing. In this case, the appearance of chempartner.com on the group’s site is a claim by the actors. No additional statements attributed specifically to lockbit3 about this victim—beyond the listing and the summarised description of exfiltrated internal files—are provided in the facts at hand.

About chempartner.com

ChemPartner is known publicly as a contract research and chemistry services organisation that has, over roughly two decades, expanded from pure chemistry support into broader research and development services for the life-sciences and pharmaceutical sector. Organisations of this type typically work with proprietary compounds, project data, analytical results, and supply-chain or logistics information related to research materials and drug candidates. They often hold contracts and technical documentation belonging to multiple client companies as well as their own internal operational records.

A breach affecting such a firm is consequential because the data environment is dense with commercially sensitive research material and, potentially, information that could identify partners, projects, or supply arrangements. Even when personal data volumes are unconfirmed, the loss of control over internal research and operational files can disrupt collaborations, raise contractual and regulatory questions, and create secondary risk for anyone whose details appear in those systems.

The information in question

The facts state that internal files were exfiltrated in a ransomware attack. The associated summary claims a volume of 281 GB and describes contents in the following terms:

• Company analytics
• Project information
• Reports
• Information on drug supplies
• Other internal material referenced only as “etc.”

Exact file inventories, whether personal data such as employee or partner contact details were included, and any confirmed exposure of regulated health or clinical information are not independently verified in the public record provided. Organisations in contract research and pharmaceutical services commonly hold project documentation, analytical datasets, supplier and logistics records, and business correspondence. Those categories align with what the listing claims, but the precise contents remain unconfirmed beyond the group’s description. No count of affected individuals has been reported.

Why it matters

For people whose names, contact details, or roles may appear in internal project or supply files, the practical risks include unwanted contact, phishing that references real project names, and social-engineering attempts that exploit knowledge of legitimate business relationships. For client companies and research partners, exposure of analytics, project files, or drug-supply information can reveal competitive research directions, timelines, or logistics arrangements that were never intended to be public.

For the organisation itself, a claimed large-scale exfiltration raises operational, contractual, and reputational issues: the need to investigate, to notify partners where required, and to assess whether any regulatory obligations apply. Because the number of people affected is unknown and the full data inventory is unconfirmed, the prudent stance is to assume that internal business material may have left the organisation’s control and to monitor for misuse rather than to treat the incident as purely theoretical. None of this establishes negligence as fact; it simply describes the ordinary consequences of a ransomware group claiming to hold a substantial internal archive.

Were you affected?

If you work with or for ChemPartner, or if you are a client, supplier, or partner whose details might appear in project or supply documentation, treat the listing as a reason for caution. Watch for unexpected emails or calls that reference real projects or colleagues. Consider changing passwords on related accounts, enabling multi-factor authentication where available, and reviewing financial or procurement channels for unusual activity. Official notifications, if any are required, would come from the organisation or from regulators; the public facts do not include such notices.

You can also run a free exposure scan of your email address to check whether your information has already appeared in known breach datasets. That step does not confirm or rule out involvement in this specific incident, but it is a practical way to see whether your credentials or contact details are circulating more broadly and to decide what further monitoring or password changes you may need.

AICompiled with AI assistance from public sources and published under our editorial standards.